Observational studyBMC cancer2025
Surgery versus stereotactic body radiotherapy for oligometastatic colorectal cancer: a prospective cohort study with propensity score matching.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal local therapy for oligometastatic colorectal cancer (CRC) remains undefined, with radical surgical resection and stereotactic body radiotherapy (SBRT) serving as the primary modalities. High-quality comparative evidence is scarce. This study aimed to prospectively compare overall survival (OS), local tumor control (LTC), quality of life (QoL), adverse events, and healthcare resource utilization between these two treatments.
methodsIn this prospective, observational cohort study, 478 patients with 1-3 oligometastases from CRC were enrolled. Treatment assignment was determined by a multidisciplinary tumor board. Propensity score matching (PSM) was used to adjust for baseline imbalances, creating 152 well-balanced pairs (n = 304) for analysis. The primary endpoint was OS; secondary endpoints included LTC, QoL (EORTC QLQ-C30), adverse events (CTCAE v5.0), and resource utilization.
resultsAfter PSM, the surgery group demonstrated a superior median OS compared to the SBRT group (65.1 months vs. 53.4 months; HR 1.48, 95% CI 1.04-2.10, p = 0.030). However, 2- and 3-year LTC rates were comparable between surgery and SBRT (87.3% vs. 86.1% and 79.8% vs. 78.2%, p = 0.220). Surgery was associated with a significantly higher incidence of major adverse events (27.6% vs. 7.9%, p < 0.001) and a greater initial decline in QoL. By 12 months, the surgery group reported superior scores in global health status and key functional domains (all p < 0.05). Healthcare resource utilization was substantially higher for surgery, with longer hospital stays, higher readmission rates, and greater costs.
conclusionIn oligometastatic CRC, surgical resection is associated with a significant overall survival advantage compared to SBRT, albeit with increased upfront morbidity, resource use, and initial QoL impairment. SBRT offers a favorable safety profile and minimal short-term disruption with comparable local control. The choice between modalities represents a critical trade-off, underscoring the need for personalized, patient-centric decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.